Does the media refer more to CYTK or PVLA?

In the previous week, Cytokinetics had 6 more articles in the media than Palvella Therapeutics. MarketBeat recorded 18 mentions for Cytokinetics and 12 mentions for Palvella Therapeutics. Cytokinetics' average media sentiment score of 0.34 beat Palvella Therapeutics' score of 0.24 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 7 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Palvella Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PRAX or PVLA more profitable?

Praxis Precision Medicines' return on equity of -34.15% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines N/A -34.15% -32.42% Palvella Therapeutics N/A -47.84% -38.33%

Does the media prefer PRAX or PVLA?

In the previous week, Palvella Therapeutics had 11 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 12 mentions for Palvella Therapeutics and 1 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.62 beat Palvella Therapeutics' score of 0.24 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Palvella Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PVLA or TGTX?

In the previous week, Palvella Therapeutics had 1 more articles in the media than TG Therapeutics. MarketBeat recorded 12 mentions for Palvella Therapeutics and 11 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.86 beat Palvella Therapeutics' score of 0.24 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TG Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is APGE or PVLA more profitable?

Apogee Therapeutics' return on equity of -29.88% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Apogee Therapeutics N/A -29.88% -28.08% Palvella Therapeutics N/A -47.84% -38.33%

Is PVLA or SYRE more profitable?

Spyre Therapeutics' return on equity of -30.74% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Palvella Therapeutics N/A -47.84% -38.33% Spyre Therapeutics N/A -30.74% -22.23%

Does the media favor PVLA or SYRE?

In the previous week, Palvella Therapeutics had 6 more articles in the media than Spyre Therapeutics. MarketBeat recorded 12 mentions for Palvella Therapeutics and 6 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.95 beat Palvella Therapeutics' score of 0.24 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spyre Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Palvella Therapeutics (PVLA) Competitors

$150.56 -3.76 (-2.44%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$150.69 +0.13 (+0.09%)

As of 09/18/2026 07:30 PM Eastern

Compare

PVLA vs. CYTK, PRAX, TGTX, APGE, and SYRE

Should you buy Palvella Therapeutics stock or one of its competitors? Palvella Therapeutics's main competitors and comparable companies include Cytokinetics (CYTK), Praxis Precision Medicines (PRAX), TG Therapeutics (TGTX), Apogee Therapeutics (APGE), and Spyre Therapeutics (SYRE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Palvella Therapeutics compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Palvella Therapeutics (NASDAQ:PVLA) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Cytokinetics presently has a consensus price target of $103.37, indicating a potential upside of 50.29%. Palvella Therapeutics has a consensus price target of $209.14, indicating a potential upside of 38.91%. Given Cytokinetics' higher probable upside, analysts plainly believe Cytokinetics is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Cytokinetics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market.

In the previous week, Cytokinetics had 6 more articles in the media than Palvella Therapeutics. MarketBeat recorded 18 mentions for Cytokinetics and 12 mentions for Palvella Therapeutics. Cytokinetics' average media sentiment score of 0.34 beat Palvella Therapeutics' score of 0.24 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	7 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palvella Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Palvella Therapeutics has lower revenue, but higher earnings than Cytokinetics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	97.21	-$784.96M	-$7.22	N/A
Palvella Therapeutics	$42.81M	50.68	-$41.72M	-$4.83	N/A

40.1% of Palvella Therapeutics shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Palvella Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-1,321.12%	N/A	-51.01%
Palvella Therapeutics	N/A	-47.84%	-38.33%

Summary

Cytokinetics beats Palvella Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Palvella Therapeutics compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Palvella Therapeutics (NASDAQ:PVLA) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Praxis Precision Medicines has a beta of 2.76, indicating that its stock price is 176% more volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market.

Praxis Precision Medicines' return on equity of -34.15% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
Palvella Therapeutics	N/A	-47.84%	-38.33%

Praxis Precision Medicines currently has a consensus price target of $612.42, indicating a potential upside of 104.86%. Palvella Therapeutics has a consensus price target of $209.14, indicating a potential upside of 38.91%. Given Praxis Precision Medicines' higher probable upside, equities research analysts clearly believe Praxis Precision Medicines is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Palvella Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	976.22	-$303.27M	-$12.93	N/A
Palvella Therapeutics	$42.81M	50.68	-$41.72M	-$4.83	N/A

67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 3.0% of Praxis Precision Medicines shares are owned by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Palvella Therapeutics had 11 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 12 mentions for Palvella Therapeutics and 1 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.62 beat Palvella Therapeutics' score of 0.24 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Palvella Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Praxis Precision Medicines beats Palvella Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Palvella Therapeutics compare to TG Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

In the previous week, Palvella Therapeutics had 1 more articles in the media than TG Therapeutics. MarketBeat recorded 12 mentions for Palvella Therapeutics and 11 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.86 beat Palvella Therapeutics' score of 0.24 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TG Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	50.68	-$41.72M	-$4.83	N/A
TG Therapeutics	$616.29M	14.12	$447.18M	$2.74	20.76

Palvella Therapeutics currently has a consensus target price of $209.14, indicating a potential upside of 38.91%. TG Therapeutics has a consensus target price of $63.00, indicating a potential upside of 10.78%. Given Palvella Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Palvella Therapeutics is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
TG Therapeutics	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Palvella Therapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market.

TG Therapeutics has a net margin of 55.22% compared to Palvella Therapeutics' net margin of 0.00%. TG Therapeutics' return on equity of 73.49% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-47.84%	-38.33%
TG Therapeutics	55.22%	73.49%	34.14%

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 17.2% of Palvella Therapeutics shares are owned by insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

TG Therapeutics beats Palvella Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Palvella Therapeutics compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Palvella Therapeutics (NASDAQ:PVLA) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Apogee Therapeutics presently has a consensus price target of $126.77, suggesting a potential downside of 6.14%. Palvella Therapeutics has a consensus price target of $209.14, suggesting a potential upside of 38.91%. Given Palvella Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Palvella Therapeutics is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Palvella Therapeutics had 12 more articles in the media than Apogee Therapeutics. MarketBeat recorded 12 mentions for Palvella Therapeutics and 0 mentions for Apogee Therapeutics. Palvella Therapeutics' average media sentiment score of 0.24 beat Apogee Therapeutics' score of 0.00 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Apogee Therapeutics	Neutral
Palvella Therapeutics	Neutral

Apogee Therapeutics has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market.

79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Palvella Therapeutics has higher revenue and earnings than Apogee Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A
Palvella Therapeutics	$42.81M	50.68	-$41.72M	-$4.83	N/A

Apogee Therapeutics' return on equity of -29.88% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-29.88%	-28.08%
Palvella Therapeutics	N/A	-47.84%	-38.33%

Summary

Palvella Therapeutics beats Apogee Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Palvella Therapeutics compare to Spyre Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Palvella Therapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 2.99, indicating that its stock price is 199% more volatile than the broader market.

Spyre Therapeutics' return on equity of -30.74% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-47.84%	-38.33%
Spyre Therapeutics	N/A	-30.74%	-22.23%

Palvella Therapeutics currently has a consensus target price of $209.14, indicating a potential upside of 38.91%. Spyre Therapeutics has a consensus target price of $109.69, indicating a potential upside of 21.54%. Given Palvella Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Palvella Therapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Palvella Therapeutics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	50.68	-$41.72M	-$4.83	N/A
Spyre Therapeutics	$890K	8,917.51	-$155.20M	-$1.95	N/A

In the previous week, Palvella Therapeutics had 6 more articles in the media than Spyre Therapeutics. MarketBeat recorded 12 mentions for Palvella Therapeutics and 6 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.95 beat Palvella Therapeutics' score of 0.24 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyre Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 17.2% of Palvella Therapeutics shares are owned by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Palvella Therapeutics beats Spyre Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Palvella Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PVLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PVLA vs. The Competition

Export

Metric	Palvella Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.22B	$3.91B	$7.25B	$13.13B
Dividend Yield	N/A	3.65%	2.57%	12.94%
P/E Ratio	-31.17	14.08	273.81	25.39
Price / Sales	50.68	1,407.75	692.78	109.00
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	63.80	15.45	10.45	6.33
Net Income	-$41.72M	-$22.78M	$3.48B	$358.24M
7 Day Performance	0.29%	-1.22%	0.88%	1.17%
1 Month Performance	0.40%	-4.44%	-1.59%	-2.59%
1 Year Performance	158.52%	37.78%	18.08%	5.97%

Palvella Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PVLA Palvella Therapeutics	2.2398 of 5 stars	$150.56 -2.4%	$209.14 +38.9%	+155.0%	$2.22B	$42.81M	N/A	29	Insider Trade High Trading Volume
CYTK Cytokinetics	2.8895 of 5 stars	$69.92 +0.8%	$103.37 +47.8%	+39.5%	$8.70B	$88.04M	N/A	673	Insider Trade
PRAX Praxis Precision Medicines	3.1019 of 5 stars	$310.47 +0.5%	$585.95 +88.7%	+561.0%	$8.67B	$8.55M	N/A	110	Positive News
TGTX TG Therapeutics	3.3775 of 5 stars	$56.47 +1.1%	$63.00 +11.6%	+74.4%	$8.64B	$616.29M	20.61	399
APGE Apogee Therapeutics	1.0608 of 5 stars	$135.07 flat	$126.77 -6.1%	N/A	$8.40B	N/A	N/A	91

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PVLA) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Palvella Therapeutics (PVLA) Competitors

PVLA vs. CYTK, PRAX, TGTX, APGE, and SYRE

How does Palvella Therapeutics compare to Cytokinetics?

Summary

How does Palvella Therapeutics compare to Praxis Precision Medicines?

Summary

How does Palvella Therapeutics compare to TG Therapeutics?

Summary

How does Palvella Therapeutics compare to Apogee Therapeutics?

Summary

How does Palvella Therapeutics compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA vs. The Competition

Palvella Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Palvella Therapeutics (PVLA) Competitors

PVLA vs. CYTK, PRAX, TGTX, APGE, and SYRE

How does Palvella Therapeutics compare to Cytokinetics?

Do analysts rate CYTK or PVLA?

Which has more risk and volatility, CYTK or PVLA?

Does the media refer more to CYTK or PVLA?

Which has preferable valuation and earnings, CYTK or PVLA?

Do institutionals and insiders believe in CYTK or PVLA?

Is CYTK or PVLA more profitable?

Summary

How does Palvella Therapeutics compare to Praxis Precision Medicines?

Which has more risk and volatility, PRAX or PVLA?

Is PRAX or PVLA more profitable?

Do analysts prefer PRAX or PVLA?

Which has higher valuation & earnings, PRAX or PVLA?

Do institutionals & insiders hold more shares of PRAX or PVLA?

Does the media prefer PRAX or PVLA?

Summary

How does Palvella Therapeutics compare to TG Therapeutics?

Does the media prefer PVLA or TGTX?

Which has preferable valuation and earnings, PVLA or TGTX?

Do analysts prefer PVLA or TGTX?

Which has more volatility and risk, PVLA or TGTX?

Is PVLA or TGTX more profitable?

Do insiders & institutionals hold more shares of PVLA or TGTX?

Summary

How does Palvella Therapeutics compare to Apogee Therapeutics?

Do analysts prefer APGE or PVLA?

Does the media refer more to APGE or PVLA?

Which has more volatility & risk, APGE or PVLA?

Do insiders and institutionals hold more shares of APGE or PVLA?

Which has higher valuation and earnings, APGE or PVLA?

Is APGE or PVLA more profitable?

Summary

How does Palvella Therapeutics compare to Spyre Therapeutics?

Which has more risk and volatility, PVLA or SYRE?

Is PVLA or SYRE more profitable?

Do analysts rate PVLA or SYRE?

Which has better valuation & earnings, PVLA or SYRE?

Does the media favor PVLA or SYRE?

Do institutionals & insiders hold more shares of PVLA or SYRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA vs. The Competition

Palvella Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools